# Prerenal Kidney Failure

Prerenal kidney failure requires rapid separation of reversible renal hypoperfusion from acute tubular injury, obstruction, and congestive cardiorenal physiology. Use trajectory, volume assessment, urine studies, medication review, targeted fluid challenge, and serial creatinine and urine output to restore perfusion without causing harmful fluid accumulation.

**Clinical question:** How should clinicians identify reversible renal hypoperfusion and manage prerenal kidney failure while excluding intrinsic and postrenal AKI?

Updated: 2026-08-24T16:53:11.006012+00:00

## What matters in practice
- Diagnose AKI when serum creatinine rises by at least 0.3 mg/dL within 48 hours, reaches at least 1.5 times baseline within 7 days, or urine output is below 0.5 mL/kg/hour for 6 hours. [13][14]
- Low urine sodium (<20 mEq/L), urine osmolality >500 mOsm/kg, and fractional excretion of sodium (FENa) <1% support sodium-avid renal hypoperfusion but do not by themselves establish volume depletion. [1][2][11]
- A monitored fluid challenge is the practical diagnostic-therapeutic test for suspected volume-responsive prerenal AKI when fluid administration is not contraindicated; improved urine output or renal function supports renal hypoperfusion. [20]
- Do not reflexively give fluids to a congested patient with acute heart failure: acute cardiorenal syndrome can produce prerenal urine indices despite hypervolemia, and recent weight trend, fluid losses, and congestion assessment direct opposite treatment. [22]
- Stop or avoid nephrotoxins and reassess drugs that reduce renal function during hypotension or dehydration, including NSAIDs, aminoglycosides, and ACE inhibitors. [1][20]
- Persistent AKI after restoration of perfusion should redirect the evaluation toward acute tubular necrosis, glomerular or interstitial disease, obstruction, or mixed injury; AKI survivors require reassessment for CKD at 3 months. [10][16][20]

## Confirm AKI and identify patients who cannot wait for a fluid trial

Establish severity, trajectory, and immediately reversible threats before assigning a prerenal mechanism.

Use KDIGO-compatible criteria to establish AKI: serum creatinine increase of at least 0.3 mg/dL within 48 hours, increase to at least 1.5 times baseline within 7 days, or urine output below 0.5 mL/kg/hour for 6 hours. Obtain serial creatinine and accurately measured urine output rather than relying on a single creatinine value, because the syndrome evolves over hours to days. [2][13][14]

Treat hemodynamic instability as a perfusion emergency while the cause is being defined. In hypovolemia, prompt crystalloid administration is recommended; in vasomotor shock or risk of AKI, fluids and vasopressors are used to support perfusion. Do not presume that all AKI with low urine sodium is volume depletion: fluids may be detrimental in cardiogenic shock or obstructive AKI. [1][18]

Review the preceding 24 to 48 hours for hemorrhage, vomiting, diarrhea, sweating, inadequate replacement of ongoing losses, sepsis, burns, pancreatitis, major surgery, hypotension, iodinated contrast exposure, and new or intensified medications. Contrast exposure, ACE inhibitor or ARB use, and NSAID exposure may be co-contributors; identify whether the medication timeline matches the creatinine rise. [2][20]
- Measure blood pressure, heart rate, daily or recent weight trend, intake/output, and current diuretic exposure before deciding whether low effective arterial volume reflects depletion or congestion. [22]
- Immediately stop or avoid NSAIDs and aminoglycosides; during hypotension or dehydration, reassess ACE inhibitors and other agents that may reduce kidney function. [1]
- If oliguria, rising creatinine, or systemic illness persists despite initial perfusion correction, broaden the evaluation rather than repeating unstructured fluid boluses. [20]

*Practical initial distinctions among low-perfusion and competing AKI mechanisms. [2][11][16][20][22]*

| Pattern | Discriminators | Next action |
| --- | --- | --- |
| Volume-responsive renal hypoperfusion | Recent gastrointestinal, hemorrhagic, or insensible losses; urine sodium <20 mEq/L; urine osmolality >500 mOsm/kg; often FENa <1%. [1][2][11] | If no contraindication, give a monitored crystalloid fluid challenge and follow urine output and renal function. [20] |
| Acute cardiorenal syndrome | Congestive heart failure physiology may coexist with FENa <1% and fractional excretion of urea <35%; weight trend and recent fluid loss or diuretic excess help distinguish congestion from depletion. [22] | Do not use urine indices alone to prescribe fluids; define congestion and hemodynamics before changing diuretic or volume strategy. [22] |
| Intrinsic tubular or inflammatory injury | Absent renal recovery after perfusion is restored; sepsis, nephrotoxins, ischemia, rhabdomyolysis, glomerular disease, or interstitial nephritis may be present. [16][20] | Reassess urine sediment, exposures, systemic features, and need for kidney-directed diagnostic escalation. [18][20] |
| Postrenal AKI | Urinary tract obstruction can produce AKI and makes indiscriminate fluid administration potentially harmful. [18] | Evaluate promptly for obstruction and correct the obstructive process. [20] |

## Use urine studies as supporting evidence, not as a substitute for clinical hemodynamics

Prerenal physiology preserves tubular sodium and water reabsorption early in the course.

Order urinalysis with microscopy, urine sodium, urine creatinine, serum sodium, serum creatinine, and urine osmolality when the result will alter the hypoperfusion-versus-intrinsic branch. A urine sodium concentration below 20 mEq/L and urine osmolality above 500 mOsm/kg support intact tubular sodium retention and concentration in renal hypoperfusion. Recent iodinated contrast can confound interpretation of high urine osmolality. [1][2]

Calculate FENa as (urine sodium × plasma creatinine) divided by (plasma sodium × urine creatinine) ×100. A FENa below 1% indicates sodium avidity and preserved tubular integrity; values above 2% to 3% favor tubular injury. Interpret this as a time-sensitive physiologic clue rather than a definitive etiologic test, because urine chemistries vary with the phase of AKI and extreme sodium avidity can produce FENa below 1% even when AKI is present. [11]

The definitive bedside discriminator for suspected volume-responsive prerenal AKI is response to a carefully monitored fluid challenge when there is no contraindication. Improvement in urine output or renal function after fluids supports renal hypoperfusion; lack of improvement should prompt reassessment for acute tubular necrosis or another intrinsic or postrenal process rather than assuming a larger fluid deficit. [20]
- A low FENa does not distinguish true intravascular depletion from low effective arterial volume in acute heart failure; both can show a prerenal pattern. [22]
- In advanced cirrhosis, FENa below 1% is common because of marked sodium avidity and should not be used alone to discriminate AKI mechanisms. [11]
- Novel biomarkers such as urinary NGAL, KIM-1, and TIMP-2/IGFBP7 remain adjunctive rather than routine replacements for clinical assessment, serial creatinine, urine output, and conventional testing. [3][13][21][22]

*Urine indices that support, but do not independently prove, prerenal physiology. [1][2][11][22]*

| Test | Prerenal-supportive result | Critical limitation |
| --- | --- | --- |
| Urine sodium | <20 mEq/L suggests avid sodium retention. [2] | Reflects renal sodium handling, not necessarily absolute volume depletion. [22] |
| Urine osmolality | >500 mOsm/kg supports preserved concentrating ability. [1] | Interpret cautiously after iodinated contrast. [1] |
| FENa | <1% supports sodium avidity; >2% to 3% suggests tubular injury. [11] | May remain <1% in advanced cirrhosis and changes with AKI phase. [11] |
| Fractional excretion of urea | <35% often accompanies prerenal physiology in acute cardiorenal syndrome. [22] | Cannot separate congestive cardiorenal physiology from hypovolemia by itself. [22] |

## Separate fluid loss, low cardiac output, and impaired autoregulation

The same low-perfusion urine pattern has different treatment implications across the major prerenal branches.

In extracellular fluid loss, the key decision is whether ongoing losses exceed replacement. Hemorrhage, vomiting, diarrhea, sweating, burns, sepsis, pancreatitis, and insufficient hospital fluid replacement all support this branch. Give crystalloid promptly when hypovolemia is present, monitor urine output and creatinine response, and continue to replace documented ongoing losses rather than using creatinine alone as the endpoint. [1][2]

In reduced cardiac output or acute cardiorenal syndrome, renal hypoperfusion can coexist with excess total body volume. Patients with stable heart failure are often mildly hypervolemic but may become hypovolemic after overaggressive diuresis, severe diarrhea, or other losses. Compare recent weight, diuretic changes, and loss history with evidence of congestion before administering fluid; misclassification can lead to fluid administration in a congested patient or unnecessary diuresis in a depleted patient. [22]

Impaired renal autoregulation is a medication-sensitive branch. NSAIDs can impair autoregulation, while ACE inhibitors and ARBs may contribute to AKI during an acute hemodynamic insult. Temporarily withholding kidney-hemodynamically active drugs in hypotension or dehydration, eliminating nephrotoxins, and adjusting medication doses to renal function are immediate actions while the precipitant is corrected. [1][16][20]

Cirrhosis requires a separate diagnostic frame because prerenal AKI, acute tubular necrosis, and hepatorenal syndrome have materially different prognosis and treatment. AKI occurs in approximately 20% of hospitalized patients with cirrhosis, and hepatorenal syndrome has the worst prognosis among these common causes, with reported survival of 35%. A low FENa is not sufficiently discriminating in advanced cirrhosis; persistent AKI after correction of reversible contributors warrants focused evaluation for ATN versus hepatorenal syndrome. [11][21]
- Consider mixed injury when an initially volume-responsive presentation has concurrent sepsis, rhabdomyolysis, hypercalcemia, or cardiac surgery exposure; each can combine reduced perfusion with direct tubular toxicity or obstruction. [16]
- Recognize that sepsis-associated AKI may occur without hypotension, so a normal blood pressure does not exclude intrinsic or mixed renal injury. [16]
- Avoid diagnosing isolated prerenal AKI solely because kidney function improves partially; prerenal and intrinsic tubular injury frequently overlap. [16][20]

## Escalate when renal function does not improve after perfusion is restored

Persistence shifts the working diagnosis away from uncomplicated reversible hypoperfusion.

If renal function and urine output do not improve after correction of a credible hemodynamic insult, reassess the three-category framework: intrinsic renal disease, obstruction, or ongoing low effective perfusion. Acute tubular necrosis may recover slowly over weeks to months, whereas prerenal physiology should improve when renal blood flow is restored. [20]

Use urinalysis and urine microscopy to seek evidence of intrinsic disease, and reconnect abnormalities to the exposure and systemic history. Ischemia, nephrotoxins, sepsis, rhabdomyolysis, glomerular disease, and acute interstitial nephritis are recognized intrinsic causes; contrast exposure and medication timing are especially important in hospitalized AKI. [16][20]

Evaluate for postrenal disease early when the history or clinical setting permits obstruction. Obstructive AKI belongs in the initial differential of every AKI evaluation, and fluids may be harmful when obstruction is the mechanism. Prompt relief of obstruction, not continued volume expansion, is the corrective intervention. [18][20]

In acute heart failure with uncertain volume status, routine pulmonary artery catheterization is not supported, although elevated filling pressures can be demonstrated invasively. Reserve invasive hemodynamic assessment for cases in which noninvasive clinical data do not resolve a management-critical uncertainty. [22]
- Consult nephrology when AKI persists despite correction of suspected hypoperfusion, when intrinsic renal disease is suspected, or when the diagnosis remains unclear after medication review, urinalysis, urine studies, and obstruction assessment. [18][20]
- For severe oliguric tubular injury with significant volume overload, diuretics may be required for volume management; they do not establish or reverse the underlying tubular injury. [20]
- Do not wait for novel biomarkers to address reversible hypoperfusion, obstruction, drug toxicity, or sepsis; their clinical role remains limited or adjunctive in routine practice. [13][21]

## Track early recovery and screen for chronic sequelae

Recovery timing informs prognosis and determines the need for longitudinal kidney surveillance.

Monitor serum creatinine and urine output after the intervention that corrected the suspected perfusion defect. Absence of AKI by both creatinine and urine-output criteria within 7 days defines recovery; reversal within 48 hours is transient AKI, whereas recovery in 2 to 7 days is persistent AKI. Lack of recovery within 7 days is termed acute kidney disease. [10]

Arrange clinical reassessment at 3 months after an AKI episode to determine whether new or worsening CKD has developed. This follow-up remains appropriate even when pre-AKI kidney function was normal, because AKI is linked to subsequent CKD through maladaptive repair and fibrosis pathways. [10]
- At follow-up, compare creatinine with the pre-AKI baseline and determine whether renal function has returned to baseline or represents new CKD. [10]
- Document the apparent precipitant, medication changes during the event, degree and duration of AKI, and whether recovery occurred by 48 hours, 7 days, or remained incomplete. [10][20]

## References
1. Acute kidney injury - Diagnosis recommendations | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/83/diagnosis-approach
2. Acute kidney injury - Diagnosis recommendations | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/83/diagnosis-recommendations
3. Cardiorenal Syndrome — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2008.07.051
4. Cardiac and Vascular Surgery–Associated Acute Kidney ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/JAHA.118.008834?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed
5. Cardiorenal Syndrome Revisited | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028814
6. Renal Effects of Intensive Volume Removal in Heart Failure ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.118.005552
7. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S027263861300471X
8. Acute Kidney Injury - Surgical Critical Care and Emergency Surgery - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781119756781.ch17
9. Acute Kidney Injury in Adults: An Underdiagnosed Condition — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1555415517306505
10. Defining Early Recovery of Acute Kidney Injury : Clinical Journal of the American Society of Nephrology — journals.lww.com — https://journals.lww.com/cjasn/fulltext/2020/09000/defining_early_recovery_of_acute_kidney_injury.22.aspx
11. Excretion Fraction - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/nursing-and-health-professions/excretion-fraction
12. Hallmarks of acute kidney injury: molecular endotypes, ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2352396426003208
13. Acute kidney injury: current concepts and new insights — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4729334
14. Prerenal Kidney Failure - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560678
15. Reading between the (guide)lines—the KDIGO practice guideline on acute kidney injury in the individual patient — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3877708
16. Acute kidney injury—an overview of diagnostic methods and clinical management — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5466115
17. [PDF] CLINICAL STUDY PROTOCOL - ClinicalTrials.gov — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/33/NCT07688733/Prot_SAP_000.pdf
18. Treatment of Acute Kidney Injury: A Review of Current ... - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11084889
19. Overview | Acute kidney injury: prevention, detection and management | Guidance | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng148
20. Acute Kidney Injury - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK441896
21. Why are patients with cirrhosis susceptible to hepatorenal syndrome (HRS)? | AASLD — www.aasld.org — https://www.aasld.org/liver-fellow-network/core-series/why-series/why-are-patients-cirrhosis-susceptible-hepatorenal
22. Acute cardiorenal syndrome: Mechanisms and clinical implications | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/85/3/231
23. Some biomarkers of acute kidney injury are increased in ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0085253815552496
24. Prerenal acute kidney injury diagnosed by urinary indices ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S221425092600096X

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.